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Discussion
Dr Paul Schipper (Portland, Ore). I appreciate what you and
your coauthors have done to evaluate the surgical treatment of
these early-stage tumors. Your historical data applied to the new
system get information out there quicker. However, you have to
be cautious when you are making prospective or clinical decisions
using retrospective pathologic data.
I have 2 questions for you based on the strong bias that exists
when you do this. When we are in the operating room, we are usu-
ally working with a combination of clinical and, if we are doing
our job right, pathologic data, but we do not have that final story.
We do not have the final pathology. Where most of the mystery
seems to lie, at least in my practice, is with the nodes that are in
the lung itself, the N1 nodes, the intraparenchymal nodes. So my
first question is, if I encounter a lesion, a 1.9-cm or T1a lesion,
and same question for a 2.5-cm or T1b lesion, N2 node negative,
good lung function, should I do a segment or a lobe? Before you
answer, if on that final pathology I find there are N1 nodes that
are positive and I did a segment, have I done the right operation?396 The Journal of Thoracic and Cardiovascular SurgDr Carr. Let’s start with the T1a lesion that is N2 negative. It is
our standard that we actually dissect out the N1 nodes associated
with the bronchovascular structures just before dividing them
and send them off as frozen. When we get those back and there
is a negative frozen section on that N1 lymph node, we then pro-
ceed immediately with an extended segmentectomy, as has been
mainly described in the Japanese literature (Okada). However, if
that N1 node comes back positive, we immediately assume there
may be additional disease we are missing, which would obviously
upstage that patient in terms of stage, and then proceed to lobec-
tomy. The same is true then for the T1b tumors. We have the
same approach to either patient. Identify N1 nodes, frozen section,
and then if positive, the patient undergoes lobectomy as opposed to
segmentectomy.
Dr Schipper.My second question then has to do with survivals.
In the Abstract, you gave us recurrence-free survival and then today
the additional information, which was very good, with the cancer-
specific survivals. Things became a little more homogeneous when
you went from one to the other. The trend that existed between bet-
ter survival with lobectomy (80%) and segmentectomy (67%) in
the T1b lesions, for example, disappeared when we looked at the
cancer-specific survival. As you pointed out, that had to do with
the fact that your patients undergoing segmentectomy were sicker.
Your comparison slide showed that very well. They had worse
FEV1, more chronic obstructive pulmonary disease, and more cor-
onary artery disease. You then proved the patients undergoing seg-
mentectomy were sicker by following them prospectively and
finding they died sooner than those undergoing lobectomy and of
cancer-unrelated causes. Because they died of these other things,
the segmentectomy cases did not have the same opportunity as
the lobectomy cases to die of lung cancer. It is a clinical decision
that we make when I evaluate somebody, and I say I don’t think
you are going to live much longer for cancer-unrelated reasons,
and therefore I am not going to give you what I perceive as the du-
rable operation, lobectomy; rather, I am going to give you a less du-
rable operation but one that is may be just as good for your specific
situation, and that is the segmentectomy.
Do your data show that segmentectomy is just as good or poten-
tially better for somebody who has a couple of decades left, some-
body who is not going to die of cancer-unrelated causes in the near
future?
Dr Carr. Initially when we started enrolling patients and seg-
mentectomies were performed, we were looking at patients who
had compromised lung function, and we were doing everything
we could to do a parenchymal-sparing operation to give them
the best quality of life and postoperative pulmonary function test
results. However, we have begun performing segmentectomies
on younger patients who have normal pulmonary function test re-
sults and are doing well. As you see, you are absolutely right, and it
is a limitation of looking at a retrospective database when you have
a difference in pulmonary function test results and the patients are
older, but the recurrence-free survival with a mean overall follow-
up overall of 45.3 months allows us to say that it is likely that a true
anatomic segmentectomy, and not just a sublobar resection but an
anatomic segmentectomy, is equivalent to a lobectomy in a patient
who has decades left to live.
DrFredericGrannis (Duarte, Calif). Thismeeting has had a re-
markable focus on health care policy and the science of health careery c February 2012
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Sdelivery, and this problem you have shown here is a casewhere you
can cure the overwhelming majority of lung cancers, but the cases
you are describing make up only 7% of all lung cancers in the
United States. Where did these cases come from? Did they come
from the screening program for computed tomography in Pitts-
burgh or from serendipity? Finally, when arewe going to stop wait-
ing for patients to develop symptoms of lung cancer, at which point
they are almost never curable, and move forward to have a health
care system where we proactively screen for these cancers?
Dr Carr.At Pittsburgh we do have a lung cancer screening pro-
gram (PLuSS) similar to the Early Lung Cancer Action Program
(Claudia Henschke) that does assist in identifying patients with
early-stage disease. In western Pennsylvania, there are only 2 large
institutions performing more advanced lung surgery like this, Al-
legheny and Pittsburgh, and Pittsburgh has more hospitals, so our
catchment is significantly higher. We are out in the community
working with the pulmonologists getting them to realize that we
do need to refer patients sooner and not wait. We’ll enroll them
in a screening process because they do have nodules, and we
will keep track of them. We have pulmonologists who are dedi-
cated and interested in just following these pulmonary nodules,
and when there are any changes they immediately refer them to us.
Your second question is a bit trickier. As time goes by, we will
be able to use screening tools, potentially genomic analysis, to risk
stratify patients as we get more robust data on screening programs
for lung cancer. However, I think we are all aware that with
changes in health care that may be coming down the pike and
the cost associated with this, we are going to need to find a cost-
effective way to screen. Until we find a cost-effective way to accu-
rately screen patients with good sensitivity and specificity, we are
still falling short. Hopefully those days are coming.
DrGrannis. I would just remind you that as time passes, 160,000
people die each year, and we do have a way to fund it, and that is
medical monitoring lawsuits against the tobacco industry.
Dr Thomas Rice (Cleveland, Ohio). I would like to propose an-
other conclusion to your study or an alternate: The best patients
with the worst cancer have a survival similar to the worst patients
with the best cancer. The problem is that this is a retrospective
study with significant bias in the selection of patients with similar
survival, which may be the result of that selection bias. To make
a fair comparison, you have to compare similar patients. ThisThe Journal of Thoracic and Caretrospective study would benefit immensely from propensity
scoring and then to compare matched groups. That would be ben-
eficial to your readers and a great addition to the literature.
Another comment is the lymph node harvest. People who un-
dergo VATS have a mean and standard deviation that are equal.
Those are skewed data, and it is better to present that as a median
plus a range. How did you handle that statistically to compare
those 2 groups? I think it has a bearing on recurrence.
Dr Carr. We agree that this is not level 1 evidence, and that
these findings will require validation by a prospective, randomized
study such as Dr Altorki’s trial (CALGB 140503).
As far as the lymph nodes are concerned, we have found that the
larger specimen associated with lobectomy produces higher lymph
node counts of final pathologic examination. The total number of
lymph node stations assessed was similar between the groups. Im-
portantly, there is no level 1 evidence to suggest that doing a more
aggressive lymph node dissection improves recurrence rates or
survival following lung resection, as demonstrated by the findings
of the ACOSOG Z0030 study.
Dr Joseph Shrager (Stanford, Calif). You end up concluding
that up to 3 cm is okay for a sublobar resection. There are a couple
of previous reports, I think you alluded to one of them, and I apol-
ogize that I do not remember where they each came from, with one
suggesting that the margin has to be at least as large as the diameter
of the tumor and one suggesting the margin has to be at least 2 cm.
You did not address anything about margins. Would you stand by
those sorts of recommendations? In other words, when is a sublo-
bar resection not appropriate?
Dr Carr. We have previously examined the issue of surgical
margins in the context of segmentectomy and found that the risk
of recurrence is diminished when surgical margin is greater than
the size of the tumor (magin:tumor ratio>1). So a 2-cm tumor
would ideally be served by a resection with a 2-cm margin. Inter-
estingly, in the current analysis we did not see any significant dif-
ference in surgical margin:tumor diameter ratios when comparing
lobectomy with segmentectomy for either T1a or T1b tumors, sug-
gesting that we are intuitively selecting the surgery that permits ad-
equate margins on an individual case-by-case basis. If we believe
that the surgical margin would be compromised with an anatomic
segmentectomy, than lobectomy should be preformed if the pa-
tient’s physiologic status permits.rdiovascular Surgery c Volume 143, Number 2 397
